Adherex Technologies Inc. (FENC) delivered earnings and revenue surprises of -9.52% and 10.61%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?...
Adherex Technologies Inc. (FENC) delivered earnings and revenue surprises of -8.33% and 100%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?...
Adherex Technologies (FENC) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Feneca Pharmaceuticals (FENC) receives FDA approval for Pedmark to reduce the risk of ototoxicity associated with cisplatin in pediatric patients with localized, non-metastatic solid tumors.
~ Under the Terms of the Investment Agreement, $5 Million to be Funded on initial closing and $20 Million to be Funded Upon Potential FDA Approval of...
The Chart of the Day belongs to the healthcare biotech company Fennec Pharmaceuticals (FENC) Barchart's Top Stocks to Own list first by the most frequent number of new highs in the last month, then used...
Here is how Bellus Health (BLU) and Adherex Technologies Inc. (FENC) have performed compared to their sector so far this year.
Here is how Adherex Technologies Inc. (FENC) and U.S. Physical Therapy (USPH) have performed compared to their sector so far this year.
RESEARCH TRIANGLE PARK, N.C., June 14, 2022 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (the “Company”) (NASDAQ:FENC) (TSX:FRX) today announced that...
Here is how Bellus Health (BLU) and Adherex Technologies Inc. (FENC) have performed compared to their sector so far this year.